We are a highly specialized and experienced group, with unique expertise in medical diagnostics technologies.
As a team, our mission is to improve patient outcomes by developing advancements and standardization in immunohistochemistry testing. We bring together outstanding physicians, scientists, and staff in a creative and supportive environment. Our goal is to spur groundbreaking advances that can then be applied to the laboratory setting.
Dr. Bogen is a Board-Certified Clinical Pathologist, having graduated from the University of Chicago Pritzker School of Medicine (M.D.) and the Weizman Institute of Science (Ph.D.), with a post-graduate residency and research fellowship at the Brigham and Women’s Hospital. He is Adjunct Professor of Pathology and Laboratory Medicine at Tufts University School of Medicine and Medical Director, Clinical Chemistry Laboratory (part-time) at Tufts Medical Center. Dr. Bogen is an inventor on 22 patents, all of which relate to various medical diagnostic technologies. In addition, he served for a decade on several NIH grant review committees, mainly for the Innovative Molecular Analysis of Cancer Technologies program sponsored by the National Cancer Institute. Dr. Bogen was previously the founder of CytoLogix Corporation, which developed the Artisan® instrument system for automated complex histopathology stains (now sold and supported by AgilentCorporation).
Mr. Falcao is an accomplished Executive / CFO with a proven track record of implementing change and driving superior business performance. He mastered executive and finance skills with Fortune 500, middle market, and start-up companies across several industries and business models (B2B, B2C, B2B2C), including a medical device company and consumer brand company. He is skilled in fostering and building complex relationships (Corporate, Investors, Customer, International Partners). Mr. Falcao is also a member of the executive team that spun-off Dunkin Brands from Allied Domecq to the consortium of Private Equity Firms (Bain, Carlyle, and TH Lee). Additionally, Mr. Falcao had ex-pat roles in Brazil, Belgium, and Malaysia, as well as conducting business in the UK, Japan, China, The Netherlands, and Spain. His CFO capabilities were further solidified through managing director assignments for APAC Business and Inside Sales Team. Mr. Falcao is a member of several non-profit boards and enjoys mentoring start-up companies.
Scott brings 20 years of experience in the immunohistochemistry and molecular diagnostic branches of the Pathology Laboratory. Scott began his career with other members of the Boston Cell Standards team at Cytologix, and then went on to work at Dako and as an original member of the Vision Biosystems North American team, later acquired by Leica (Danaher). Scott has worked for several VC-backed start-up companies in the molecular diagnostics space, and most recently was Global Vice President of Sales, Service, and Field Support at Biocare Medical. Scott received a BS in Chemistry and a BA in English/Journalism from the University of Delaware.
Ms. Vani has over 20 years of laboratory experience in biochemistry and molecular biology and has operational responsibility for BCS’s cGMP manufacturing processes. After receiving a Masters degree in Chemistry, she initially worked in Drosophila genetics at Columbia University, NY and later in R&D at CytoLogix Corp., Cambridge MA. She has a broad range of research laboratory expertise, covering molecular biology, immunology, and pathology, and is a co-author on numerous peer-reviewed journal articles.
Dr. Zeheb brings to BCS a 25-year track record of successfully developing and launching medical diagnostic products. He received his PhD in biochemistry from the Albert Einstein College of Medicine of Yeshiva University. At Oncogene Science, Inc., he initiated and developed a new product line of quantitative immunoassays resulting in the commercialization of the company’s first ELISA kits. As Director of R&D for Ventana Medical Systems, he led the team that developed the first instrument for automating in situ hybridization assays. He was the founding Vice President of Research at CytoLogix Corporation, where he directed the development of the Artisan® staining platform and associated staining kits for both immunohistochemical and special stains applications. Dr. Zeheb was Senior Vice President of Research and Development at Dako Corporation (US) and the Director of Molecular and Immunohistochemical Laboratories in the Department of Anatomic Pathology of the Lahey Clinic. He has authored numerous publications and patents, and been the recipient of NIH and private research grants.
Dr. Radcliffe (Radcliffe Consulting, Inc.) has more than 20 years of experience assisting medical device and diagnostics companies with technical assessment, marketing, and clinical/regulatory issues. Gail was awarded her PhD in Molecular Biology from Brown University and completed a post-doctoral fellowship in molecular immunology at the University of Massachusetts Medical School. Afterward, she worked at GENE-TRAK and then Cytyc, until 1998, when she founded Radcliffe Consulting, Inc. Dr. Radcliffe consults with medical device companies, for market research, regulatory strategy (IVD vs. CLIA lab) and submissions, quality systems development, and clinical trial support. Her experience includes a wide range of products in digital pathology, laser dissection devices, companion diagnostics, and multiplex molecular, POC and CLIA Waived in vitro diagnostic devices.